Improving the Quality of Two Lives by Treating Obesity

Improving the Quality of Two Lives by Treating Obesity

<b>Background and Clinical Significance:</b> Kidney transplantation remains the most effective method of renal replacement therapy. Living donor transplantation offers several advantages—reduced cardiovascular risk, better graft survival, and preemptive intervention. However, donor obesi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Norbert Nagy, Patrícia Kleinová, Martin Jozef Péč, Matej Samoš, Ivana Dedinská
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Reports
Subjects:	obesity treatment living kidney donation GLP-1 receptor agonist
Online Access:	https://www.mdpi.com/2571-841X/8/2/85
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

GLP-1 Agonists, Willpower, and Weight Stigma: A Paradigm Shift for Obesity
by: Pablo Arrona-Cardoza
Published: (2025-08-01)

Saudi Healthcare Providers’ Perspectives and Clinical Practice of Anti-Obesity Medications: A National Survey
by: Haifa F. AlOtaibi, et al.
Published: (2025-07-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety
by: Michał Stasiak, et al.
Published: (2025-06-01)

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
by: Gentinetta S, et al.
Published: (2024-12-01)

REBOUND OBESITY AFTER GLP-1 AGONISTS DISCONTINUATION
by: Zainab M. Al-Shammaa, et al.
Published: (2025-07-01)

The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-07-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice
by: Fang Lv, et al.
Published: (2024-12-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

Oral semaglutide for the treatment of obesity: a retrospective real-world study
by: Mitja Krajnc, et al.
Published: (2025-05-01)

Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity
by: Alzahrani AM, et al.
Published: (2025-04-01)

Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
by: Wenwen Zheng, et al.
Published: (2025-08-01)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
by: Yue Yin, et al.
Published: (2025-04-01)

Implementation of a 1-Day Living Kidney Donor Evaluation Program: A Qualitative Analysis of Donor Candidate and Stakeholder Perspectives
by: Lindsay Reid, et al.
Published: (2024-02-01)

Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis
by: Song Liu, et al.
Published: (2025-02-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
by: Mohammed Sallam, et al.
Published: (2025-04-01)

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ligang Liu, et al.
Published: (2025-04-01)

Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence
by: Natalia Gniaź, et al.
Published: (2024-12-01)

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants
by: Amirah Alhowiti, et al.
Published: (2025-07-01)

Tirzepatide - role in obesity, health and physical wellness. Information overview
by: Anna Hanslik, et al.
Published: (2025-02-01)

Pulmonary artery pressure trajectories in heart failure patients treated with GLP‐1 receptor agonists
by: Haoran Jiang, et al.
Published: (2025-08-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
by: Paweł Kukiełka, et al.
Published: (2025-07-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Are GLP-1 Analogues a New Solution for the Treatment of NAFLD?
by: Maria Sudoł, et al.
Published: (2024-12-01)

Transformative weight loss with Dulaglutide: A case report of success in a challenging patient profile of an ex‐sumo wrestler
by: Sohail Bade, et al.
Published: (2024-09-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Exploring Glucagon‐Like Peptide‐1 Receptor Agonists Usage Among Non‐Diabetic Healthcare Providers: A Cross‐Sectional Multi‐Country Study
by: Abdulqadir J. Nashwan, et al.
Published: (2025-04-01)

Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
by: Ansel Shao Pin Tang, et al.
Published: (2025-07-01)

Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
by: Miodrag Janić, et al.
Published: (2024-11-01)

Synergy of pharmacotherapy and physical activity in the treatment of obesity and cardiovascular prevention in patients with type 2 diabetes
by: Karolina Mędrysa, et al.
Published: (2025-06-01)

The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis
by: Yan Xu, et al.
Published: (2025-04-01)